Skip to main content

Table 3 Baseline characteristics of the ITT population and patients who completed the AQLQ at least once during the study

From: Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life

 

ITT population

AQLQ populationa

Characteristics

SAL/FP

FOR/BUD

SAL/FP

FOR/BUD

No. of patients

344

344

280

288

Age, mean (SD), years

46 (14)

44 (14)

45 (14)

44 (14)

Sex, female no. (%)

204 (59)

216 (63)

156 (56)

178 (62)

Asthma Duration ≥ 10 years no.(%)

197 (57)

200 (58)

171 (61)

162 (56)

FEV1, mean (SD), L

2.53 (0.80)

2.52 (0.70)

2.57 (0.83)

2.49 (0.68)

FEV1, mean (SD), % predicted

82 (21)

81 (13)

82 (23)

80 (12)

Daily asthma symptom score, mean (SD)

1.9 (0.6)

1.9 (0.5)

2.0 (0.6)

1.9 (0.6)

AQLQ overall score, mean (SD)

  

4.8 (1.0)

4.8 (0.9)

  1. AQLQ = Asthma Quality of Life Questionnaire; FOR/BUD = formoterol/budesonide combination; ITT = intent to treat; SAL/FP = salmeterol/fluticasone propionate combination; SD = standard deviation.
  2. a ITT patients who completed at least one AQLQ questionnaire.